Kulbhushan Sharma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kulbhushan Sharma has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
Madhuri Chaurasia
Institute of Nuclear Medicine and Allied Sciences, DRDO, Delhi, India
4 shared publications- Sunil Kumar Lal
Virology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
3 shared publications Alo Nag
Department of Biochemistry, University of Delhi, New Delhi, India
2 shared publications- Anne Simonsen
Department of Molecular Medicine, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo
2 shared publications Asmita Das
B Department of Biotechnology , Delhi Technological University , Delhi , India
2 shared publications- Bilikere Srinivasarao Dwarakanath
Division of Radiation Biosciences, Institute of Nuclear Medicine and Allied Sciences, Delhi, India
2 shared publications
Latest Publications
- Open Access
Generation and characterization of a patient-specific human induced pluripotent stem cell line from a Skogholt syndrome patient (ASCFi003-A)
We report the generation and characterization of a human induced pluripotent stem cell (iPSC) line derived from dermal fibroblasts of a patient with Skogholt’s disease, a rare maternally inherited neurodegenerative syndrome associated with choroid plexus dysfunction and impaired cerebrospinal fluid (CSF) homeostasis. Patient fibroblasts were reprogrammed using the non-integrating Repro-OSKGM kit. The resulting iPSC line exhibited typical pluripotent morphology, expressed canonical pluripotency markers, maintained a normal karyotype, retained the disease-associated genetic variant, was mycoplasma-free, and demonstrated trilineage differentiation potential. We also made choroid plexus (ChP) like organoids from the generated iPSCs. This patient-specific iPSC line provides a valuable resource for generating choroid plexus organoids and neurons to investigate disease mechanisms and develop therapeutic strategies.
Open AccessGeneration and characterization of a patient-specific human induced pluripotent stem cell line from a Skogholt syndrome patient (ASCFi003-A)
We report the generation and characterization of a human induced pluripotent stem cell (iPSC) line derived from dermal fibroblasts of a patient with Skogholt’s disease, a rare maternally inherited neurodegenerative syndrome associated with choroid plexus dysfunction and impaired cerebrospinal fluid (CSF) homeostasis. Patient fibroblasts were reprogrammed using the non-integrating Repro-OSKGM kit. The resulting iPSC line exhibited typical pluripotent morphology, expressed canonical pluripotency markers, maintained a normal karyotype, retained the disease-associated genetic variant, was mycoplasma-free, and demonstrated trilineage differentiation potential. We also made choroid plexus (ChP) like organoids from the generated iPSCs. This patient-specific iPSC line provides a valuable resource for generating choroid plexus organoids and neurons to investigate disease mechanisms and develop therapeutic strategies.
- Open Access
Targeting Autophagy Accelerates Intestinal Repair after Acute Ionizing Radiation
Radiation exposure induces systemic and cellular damage, contributing to acute radiation syndrome and long-term effects such as premature aging and carcinogenesis. At the cellular level, radiation triggers apoptosis, mutation, and transformation through oxidative damage and activation of pathways including ER stress–mediated autophagy. Autophagy plays a context-dependent dual role in stressed cells, but its contribution to intestinal recovery after acute radiation remains unclear. Here, we evaluated combinatorial radiomodification using gamma radiation (8 Gy) and autophagy modulators in whole-body irradiated C57BL/6 mice (8–10 weeks old, n = 10). Mice were treated with autophagy inducers or inhibitors and euthanized at 3-, 8-, and 30-day post-irradiation. The jejunal–ileal region was analyzed via antioxidant assays, immunoblotting, H&E staining, and immunohistochemistry. Radiation significantly altered oxidative stress and autophagy markers, including increased LC3-II and decreased SQSTM1/p62. Autophagy induction enhanced intestinal proliferation (as measured by Ki-67), whereas inhibition impaired regeneration. Rapamycin pretreatment improved survival and reduced markers of intestinal injury following 8 Gy total body irradiation (TBI), whereas chloroquine exacerbated several injury-associated parameters. Overall, our findings suggest that targeted modulation of autophagy is a promising strategy for alleviating radiation-induced gastrointestinal injury and provide mechanistic insights relevant to therapeutic development.
Open AccessTargeting Autophagy Accelerates Intestinal Repair after Acute Ionizing Radiation
Radiation exposure induces systemic and cellular damage, contributing to acute radiation syndrome and long-term effects such as premature aging and carcinogenesis. At the cellular level, radiation triggers apoptosis, mutation, and transformation through oxidative damage and activation of pathways including ER stress–mediated autophagy. Autophagy plays a context-dependent dual role in stressed cells, but its contribution to intestinal recovery after acute radiation remains unclear. Here, we evaluated combinatorial radiomodification using gamma radiation (8 Gy) and autophagy modulators in whole-body irradiated C57BL/6 mice (8–10 weeks old, n = 10). Mice were treated with autophagy inducers or inhibitors and euthanized at 3-, 8-, and 30-day post-irradiation. The jejunal–ileal region was analyzed via antioxidant assays, immunoblotting, H&E staining, and immunohistochemistry. Radiation significantly altered oxidative stress and autophagy markers, including increased LC3-II and decreased SQSTM1/p62. Autophagy induction enhanced intestinal proliferation (as measured by Ki-67), whereas inhibition impaired regeneration. Rapamycin pretreatment improved survival and reduced markers of intestinal injury following 8 Gy total body irradiation (TBI), whereas chloroquine exacerbated several injury-associated parameters. Overall, our findings suggest that targeted modulation of autophagy is a promising strategy for alleviating radiation-induced gastrointestinal injury and provide mechanistic insights relevant to therapeutic development.
- Open Access
- 17 September 2024
- Published by MDPI AG in Journal of Clinical & Translational Ophthalmology
- Vol. 2 (3) , 99-112
Rapamycin’s Impact on Age-Related Macular Degeneration—A Systematic Review and Hormesis Perspective
Background: Pre-clinical studies related to the use of rapamycin (Sirolimus®), a mammalian target of rapamycin (mTOR) inhibitors, for age-related macular degeneration (AMD) have shown improved therapeutic outcomes. However, knowledge of its dose–effect relationship in humans with AMD has been limited and requires further investigation. Objective: The aim of this study is to assess the safety and efficacy of Sirolimus® for treatment of AMD in humans and determine the dose range for its application in the eye. Methods: A systematic literature review was conducted following the PRISMA guidelines. The MEDLINE, Embase, CINAHL, Scopus and Cochrane Central Registry of Controlled Trials databases were searched for original clinical studies examining the effects of Sirolimus® on outcomes linked to AMD in humans. This review has been registered in the PROSPERO database. Results: Only four studies were found to satisfy the inclusion and exclusion criteria and were analyzed in this systematic review in a narrative way. The dose range of rapamycin in the limited number of studies appears to be toxic to the retina. Conclusion: Future studies should focus on establishing the optimal low-dose range of Sirolimus® that effectively induces autophagy without causing retinal toxicity, as current data indicate a potential therapeutic window that remains underexplored. Specifically, longitudinal, controlled studies with larger, heterogeneous patient populations are necessary to determine the precise dosing that balances efficacy and safety in treating AMD.
- 17 September 2024
- Published by MDPI AG in Journal of Clinical & Translational Ophthalmology
- Vol. 2 (3) , 99-112
Open AccessRapamycin’s Impact on Age-Related Macular Degeneration—A Systematic Review and Hormesis Perspective
Background: Pre-clinical studies related to the use of rapamycin (Sirolimus®), a mammalian target of rapamycin (mTOR) inhibitors, for age-related macular degeneration (AMD) have shown improved therapeutic outcomes. However, knowledge of its dose–effect relationship in humans with AMD has been limited and requires further investigation. Objective: The aim of this study is to assess the safety and efficacy of Sirolimus® for treatment of AMD in humans and determine the dose range for its application in the eye. Methods: A systematic literature review was conducted following the PRISMA guidelines. The MEDLINE, Embase, CINAHL, Scopus and Cochrane Central Registry of Controlled Trials databases were searched for original clinical studies examining the effects of Sirolimus® on outcomes linked to AMD in humans. This review has been registered in the PROSPERO database. Results: Only four studies were found to satisfy the inclusion and exclusion criteria and were analyzed in this systematic review in a narrative way. The dose range of rapamycin in the limited number of studies appears to be toxic to the retina. Conclusion: Future studies should focus on establishing the optimal low-dose range of Sirolimus® that effectively induces autophagy without causing retinal toxicity, as current data indicate a potential therapeutic window that remains underexplored. Specifically, longitudinal, controlled studies with larger, heterogeneous patient populations are necessary to determine the precise dosing that balances efficacy and safety in treating AMD.
- 31 December 2021
- Published by Wiley in Alzheimer's & Dementia
- Vol. 17 (S5) , e056329
Regulation of intracellular innate immune amyloid beta (aβ) clearance
Background: Innate immune Aβ clearance may be involved in Alzheimer’s disease (AD) etiology and treatment response following anti‐amyloid immunotherapy. Regulation of intracellular Aβ clearance is not measured in AD risk‐ or diagnostic assessments, and pathways and mechanisms are insufficiently mapped. We present assays for Aβ catalysis in myeloid cells (THP‐1 cells and human iPSC microglia).Method: THP‐1 cells were differentiated toward macrophages, and treated with various inhibitors including IDE inhibitor (6bK, Tocris),BACE1 inhibitor (LY2886721, Tocris), Nep inhibitor (Phosphoramidon, Tocris), Bafilomycin A1(Sigma)(1h) and Rapamycin (Sigma) (18h) before adding 100 ng/ml Aβ40 (2h), followed by 4h chase. For AD patient derived microglia, reprogrammed iPSCs were differentiated through a myeloid progenitor stage. Mature microglia were characterized by qPCR, Immunofluorescence and phagocytosis assay. Two immunoassays were developed on the Simoa platform using proprietary sheep monoclonal antibodies (Pre Diagnostics, Norway). Both assays employ an Aβ c‐terminal antibody for capture (AB.4D7). Assay 20‐x employs a specific Aβ20’ cut point antibody (NH2‐20.2B8) and assay x‐40 a linear mid‐domain antibody (AB.2A9) binding full length Aβ as detector.Result: 1) Innate immune cells (THP1, microglia) catabolize Aβ 1‐40 producing 20‐x fragments. 2) Inhibition of Nep and BACE1 reduces the production of 20‐x fragment of Aβ in THP1 cells. 3) Autophagy inhibitor BafA1 increases both 1‐40 and 20‐x fragments indicating the role of the endo‐lysosomal system in the degradation of full length and 20‐x Aβ. 4) Autophagy inducer, Rapamycin reduces both 1‐40 and 20‐x fragments indicating the role of mTOR mediated autophagy and the endo‐lysosomal system in the degradation of full length and 20‐x Aβ.Conclusion: 1) We demonstrate a novel assay for Aβ degradation by Innate immune cells including THP‐1 and iPSC derived microglia. 2) Inhibition of Nep and BACE1 reduces 20‐x peptide generation indicating this as a potential marker for Aβ. 3) Modulation of autophagy affects 20‐x peptide generation indicating the potential of targeting endo‐lysosomal and autophagic pathway against AD.
- 31 December 2021
- Published by Wiley in Alzheimer's & Dementia
- Vol. 17 (S5) , e056329
Regulation of intracellular innate immune amyloid beta (aβ) clearance
Background: Innate immune Aβ clearance may be involved in Alzheimer’s disease (AD) etiology and treatment response following anti‐amyloid immunotherapy. Regulation of intracellular Aβ clearance is not measured in AD risk‐ or diagnostic assessments, and pathways and mechanisms are insufficiently mapped. We present assays for Aβ catalysis in myeloid cells (THP‐1 cells and human iPSC microglia).Method: THP‐1 cells were differentiated toward macrophages, and treated with various inhibitors including IDE inhibitor (6bK, Tocris),BACE1 inhibitor (LY2886721, Tocris), Nep inhibitor (Phosphoramidon, Tocris), Bafilomycin A1(Sigma)(1h) and Rapamycin (Sigma) (18h) before adding 100 ng/ml Aβ40 (2h), followed by 4h chase. For AD patient derived microglia, reprogrammed iPSCs were differentiated through a myeloid progenitor stage. Mature microglia were characterized by qPCR, Immunofluorescence and phagocytosis assay. Two immunoassays were developed on the Simoa platform using proprietary sheep monoclonal antibodies (Pre Diagnostics, Norway). Both assays employ an Aβ c‐terminal antibody for capture (AB.4D7). Assay 20‐x employs a specific Aβ20’ cut point antibody (NH2‐20.2B8) and assay x‐40 a linear mid‐domain antibody (AB.2A9) binding full length Aβ as detector.Result: 1) Innate immune cells (THP1, microglia) catabolize Aβ 1‐40 producing 20‐x fragments. 2) Inhibition of Nep and BACE1 reduces the production of 20‐x fragment of Aβ in THP1 cells. 3) Autophagy inhibitor BafA1 increases both 1‐40 and 20‐x fragments indicating the role of the endo‐lysosomal system in the degradation of full length and 20‐x Aβ. 4) Autophagy inducer, Rapamycin reduces both 1‐40 and 20‐x fragments indicating the role of mTOR mediated autophagy and the endo‐lysosomal system in the degradation of full length and 20‐x Aβ.Conclusion: 1) We demonstrate a novel assay for Aβ degradation by Innate immune cells including THP‐1 and iPSC derived microglia. 2) Inhibition of Nep and BACE1 reduces 20‐x peptide generation indicating this as a potential marker for Aβ. 3) Modulation of autophagy affects 20‐x peptide generation indicating the potential of targeting endo‐lysosomal and autophagic pathway against AD.
- Open Access
- 20 December 2021
- Published by Taylor & Francis in Autophagy
- Vol. 18 (8) , 1915-1931
Autophagy modulates cell fate decisions during lineage commitment
Early events during development leading to exit from a pluripotent state and commitment toward a specific germ layer still need in-depth understanding. Autophagy has been shown to play a crucial role in both development and differentiation. This study employs human embryonic and induced pluripotent stem cells to understand the early events of lineage commitment with respect to the role of autophagy in this process. Our data indicate that a dip in autophagy facilitates exit from pluripotency. Upon exit, we demonstrate that the modulation of autophagy affects SOX2 levels and lineage commitment, with induction of autophagy promoting SOX2 degradation and mesendoderm formation, whereas inhibition of autophagy causes SOX2 accumulation and neuroectoderm formation. Thus, our results indicate that autophagy-mediated SOX2 turnover is a determining factor for lineage commitment. These findings will deepen our understanding of development and lead to improved methods to derive different lineages and cell types. Abbreviations: ACTB: Actin, beta; ATG: Autophagy-related; BafA1: Bafilomycin A1; CAS9: CRISPR-associated protein 9; CQ: Chloroquine; DE: Definitive endoderm; hESCs: Human Embryonic Stem Cells; hiPSCs: Human Induced Pluripotent Stem Cells; LAMP1: Lysosomal Associated Membrane Protein 1; MAP1LC3: Microtubule-Associated Protein 1 Light Chain 3; MTOR: Mechanistic Target Of Rapamycin Kinase; NANOG: Nanog Homeobox; PAX6: Paired Box 6; PE: Phosphatidylethanolamine; POU5F1: POU class 5 Homeobox 1; PRKAA2: Protein Kinase AMP-Activated Catalytic Subunit Alpha 2; SOX2: SRY-box Transcription Factor 2; SQSTM1: Sequestosome 1; ULK1: unc-51 like Autophagy Activating Kinase 1; WDFY3: WD Repeat and FYVE Domain Containing 3.
- 20 December 2021
- Published by Taylor & Francis in Autophagy
- Vol. 18 (8) , 1915-1931
Open AccessAutophagy modulates cell fate decisions during lineage commitment
Early events during development leading to exit from a pluripotent state and commitment toward a specific germ layer still need in-depth understanding. Autophagy has been shown to play a crucial role in both development and differentiation. This study employs human embryonic and induced pluripotent stem cells to understand the early events of lineage commitment with respect to the role of autophagy in this process. Our data indicate that a dip in autophagy facilitates exit from pluripotency. Upon exit, we demonstrate that the modulation of autophagy affects SOX2 levels and lineage commitment, with induction of autophagy promoting SOX2 degradation and mesendoderm formation, whereas inhibition of autophagy causes SOX2 accumulation and neuroectoderm formation. Thus, our results indicate that autophagy-mediated SOX2 turnover is a determining factor for lineage commitment. These findings will deepen our understanding of development and lead to improved methods to derive different lineages and cell types. Abbreviations: ACTB: Actin, beta; ATG: Autophagy-related; BafA1: Bafilomycin A1; CAS9: CRISPR-associated protein 9; CQ: Chloroquine; DE: Definitive endoderm; hESCs: Human Embryonic Stem Cells; hiPSCs: Human Induced Pluripotent Stem Cells; LAMP1: Lysosomal Associated Membrane Protein 1; MAP1LC3: Microtubule-Associated Protein 1 Light Chain 3; MTOR: Mechanistic Target Of Rapamycin Kinase; NANOG: Nanog Homeobox; PAX6: Paired Box 6; PE: Phosphatidylethanolamine; POU5F1: POU class 5 Homeobox 1; PRKAA2: Protein Kinase AMP-Activated Catalytic Subunit Alpha 2; SOX2: SRY-box Transcription Factor 2; SQSTM1: Sequestosome 1; ULK1: unc-51 like Autophagy Activating Kinase 1; WDFY3: WD Repeat and FYVE Domain Containing 3.
- Open Access
Crosstalk between Different DNA Repair Pathways Contributes to Neurodegenerative Diseases
Genomic integrity is maintained by DNA repair and the DNA damage response (DDR). Defects in certain DNA repair genes give rise to many rare progressive neurodegenerative diseases (NDDs), such as ocular motor ataxia, Huntington disease (HD), and spinocerebellar ataxias (SCA). Dysregulation or dysfunction of DDR is also proposed to contribute to more common NDDs, such as Parkinson’s disease (PD), Alzheimer’s disease (AD), and Amyotrophic Lateral Sclerosis (ALS). Here, we present mechanisms that link DDR with neurodegeneration in rare NDDs caused by defects in the DDR and discuss the relevance for more common age-related neurodegenerative diseases. Moreover, we highlight recent insight into the crosstalk between the DDR and other cellular processes known to be disturbed during NDDs. We compare the strengths and limitations of established model systems to model human NDDs, ranging from C. elegans and mouse models towards advanced stem cell-based 3D models.
Open AccessCrosstalk between Different DNA Repair Pathways Contributes to Neurodegenerative Diseases
Genomic integrity is maintained by DNA repair and the DNA damage response (DDR). Defects in certain DNA repair genes give rise to many rare progressive neurodegenerative diseases (NDDs), such as ocular motor ataxia, Huntington disease (HD), and spinocerebellar ataxias (SCA). Dysregulation or dysfunction of DDR is also proposed to contribute to more common NDDs, such as Parkinson’s disease (PD), Alzheimer’s disease (AD), and Amyotrophic Lateral Sclerosis (ALS). Here, we present mechanisms that link DDR with neurodegeneration in rare NDDs caused by defects in the DDR and discuss the relevance for more common age-related neurodegenerative diseases. Moreover, we highlight recent insight into the crosstalk between the DDR and other cellular processes known to be disturbed during NDDs. We compare the strengths and limitations of established model systems to model human NDDs, ranging from C. elegans and mouse models towards advanced stem cell-based 3D models.
- 1 August 2019
- Published by Elsevier in Pediatric Dental Journal
- Vol. 29 (2) , 84-89
Prevalence of dental fear and its relationship with primary dental caries in 7-year-old-children
- 1 August 2019
- Published by Elsevier in Pediatric Dental Journal
- Vol. 29 (2) , 84-89
Prevalence of dental fear and its relationship with primary dental caries in 7-year-old-children
- Open Access
- 13 June 2019
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 10, 554
Peroxisome Proliferator Activated Receptor Gamma Sensitizes Non-small Cell Lung Carcinoma to Gamma Irradiation Induced Apoptosis
The nuclear receptors known as peroxisome proliferator activated receptor gamma (PPARG) are lipid-activated transcription factors that have emerged as key regulators of inflammation. PPARG ligands have been shown to have an anti-proliferative effect on a variety of cancers. These ligands can induce apoptosis via TP53 (Tumor protein p53) or ERK1/2 (Extracellular signal-regulated kinases 1/2) (EPHB2) pathways. However, the exact mechanism is not known. PPAR, a type II nuclear hormone receptor deserves attention as a selective target for radiotherapy. Our study examines the potential of selective agonism of PPARG for radiation therapy in non-small cell lung carcinoma (NSCLC). We found that the overexpression of PPARG protein as well as its induction using the agonist, rosiglitazone was able to stimulate radiation-induced cell death in otherwise radio resistant NSCLC A549 cell line. This cell death was apoptotic and was found to be BAX (BCL2 associated X) mediated. The treatment also inhibited radiation-induced AKT (Protein Kinase B) phosphorylation. Interestingly, the ionising radiation (IR) induced apoptosis was found to be inversely related to TP53 levels. A relatively significant increase in the levels of radiation induced apoptosis was observed in H1299 cells (TP53 null) under PPARG overexpression condition further supporting the inverse relationship between apoptosis and TP53 levels. The combination of PPARG agonist and radiation was able to induce apoptosis at a radiation dose at which A549 and H1299 are radioresistant, thus confirming the potential of the combinatorial strategy. Taken together, PPARG agonism was found to invigorate the radiosensitising effect and hence its use in combination with radiotherapy is expected to enhance sensitivity in otherwise resistant cancer types.
- 13 June 2019
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 10, 554
Open AccessPeroxisome Proliferator Activated Receptor Gamma Sensitizes Non-small Cell Lung Carcinoma to Gamma Irradiation Induced Apoptosis
The nuclear receptors known as peroxisome proliferator activated receptor gamma (PPARG) are lipid-activated transcription factors that have emerged as key regulators of inflammation. PPARG ligands have been shown to have an anti-proliferative effect on a variety of cancers. These ligands can induce apoptosis via TP53 (Tumor protein p53) or ERK1/2 (Extracellular signal-regulated kinases 1/2) (EPHB2) pathways. However, the exact mechanism is not known. PPAR, a type II nuclear hormone receptor deserves attention as a selective target for radiotherapy. Our study examines the potential of selective agonism of PPARG for radiation therapy in non-small cell lung carcinoma (NSCLC). We found that the overexpression of PPARG protein as well as its induction using the agonist, rosiglitazone was able to stimulate radiation-induced cell death in otherwise radio resistant NSCLC A549 cell line. This cell death was apoptotic and was found to be BAX (BCL2 associated X) mediated. The treatment also inhibited radiation-induced AKT (Protein Kinase B) phosphorylation. Interestingly, the ionising radiation (IR) induced apoptosis was found to be inversely related to TP53 levels. A relatively significant increase in the levels of radiation induced apoptosis was observed in H1299 cells (TP53 null) under PPARG overexpression condition further supporting the inverse relationship between apoptosis and TP53 levels. The combination of PPARG agonist and radiation was able to induce apoptosis at a radiation dose at which A549 and H1299 are radioresistant, thus confirming the potential of the combinatorial strategy. Taken together, PPARG agonism was found to invigorate the radiosensitising effect and hence its use in combination with radiotherapy is expected to enhance sensitivity in otherwise resistant cancer types.
- 20 March 2019
- Published by Taylor & Francis in Autophagy
- Vol. 15 (8) , 1391-1406
Radiation induces EIF2AK3/PERK and ERN1/IRE1 mediated pro-survival autophagy
Cellular effects of ionizing radiation include oxidative damage to macromolecules, unfolded protein response (UPR) and metabolic imbalances. Oxidative stress and UPR have been shown to induce macro...
- 20 March 2019
- Published by Taylor & Francis in Autophagy
- Vol. 15 (8) , 1391-1406
Radiation induces EIF2AK3/PERK and ERN1/IRE1 mediated pro-survival autophagy
Cellular effects of ionizing radiation include oxidative damage to macromolecules, unfolded protein response (UPR) and metabolic imbalances. Oxidative stress and UPR have been shown to induce macro...
- 26 October 2018
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 19 (15) , 1818-1830
PPARγ-targeting Potential for Radioprotection
Peroxisomal proliferator receptor gamma (PPARγ) is a class of nuclear hormone receptor family involved in insulin sensitization. In addition, PPARγ has a key role in the protection against oxidative stress and inflammation through regulation of NFkappaB levels and cross-talk with the Nrf-2 pathway. Also, its role in the modulation of immune response is substantial. Radiation-induced oxidative stress is the sole determinant of damage to hematopoietic, gastrointestinal system and immune system suppression. Uncontrolled exposure to normal cells during radiotherapy raises the demand for novel and efficient radioprotectors. In this review, we will present an overview of the involvement of PPARγ in radiation-induced damage and inflammation with major emphasis on whether PPARγ can serve as a suitable radiomodification target.
- 26 October 2018
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 19 (15) , 1818-1830
PPARγ-targeting Potential for Radioprotection
Peroxisomal proliferator receptor gamma (PPARγ) is a class of nuclear hormone receptor family involved in insulin sensitization. In addition, PPARγ has a key role in the protection against oxidative stress and inflammation through regulation of NFkappaB levels and cross-talk with the Nrf-2 pathway. Also, its role in the modulation of immune response is substantial. Radiation-induced oxidative stress is the sole determinant of damage to hematopoietic, gastrointestinal system and immune system suppression. Uncontrolled exposure to normal cells during radiotherapy raises the demand for novel and efficient radioprotectors. In this review, we will present an overview of the involvement of PPARγ in radiation-induced damage and inflammation with major emphasis on whether PPARγ can serve as a suitable radiomodification target.